Effect of PARP Inhibitors Maintenance Therapy on the Survival Rate of Advanced or Relapsed Epitherlial Ovarian Cancer: an Observational Cohort Study

Shanghai Gynecologic Oncology Group0 个研究点目标入组 6,000 人开始时间: 2025年3月最近更新: 2025年2月20日

试验速览

阶段: 不适用
状态: 尚未招募
发起方
入组人数: 6,000
主要终点: Overall Mortality

研究概览研究设计入排标准结局指标研究者记录与标识符相似试验

研究概览

简要总结

With the widespread use of PARP inhibitors (PARPi) as maintenance therapy in ovarian cancer, there is still a lack of real-world data from large samples regarding their impact on survival outcomes in advanced and recurrent ovarian cancer. This study aims to conduct a pragmatic cohort study to evaluate the impact of first-line and second-line maintenance treatment with PARPi on survival rates in patients with advanced and recurrent ovarian cancer. The genetic status, different PARPi drugs, and the use of anti-angiogenic inhibitor maintenance therapy or not is used as confounding factors.

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Retrospective

入排标准

年龄范围: 18 Years 至 80 Years（Adult, Older Adult）
性别: Female
接受健康志愿者: 否

入选标准

•Patients newly diagnosed with stage IIIC or IV primary epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer between December 2013 and December
•Complete data on first-line treatment and maintenance therapy.
•Availability of follow-up data.
•Patients with platinum-sensitive first recurrence of any stage of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, diagnosed between December 2013 and December
•Disease progression occurring at least 6 months after the completion of the last platinum-based chemotherapy regimen.
•Complete data on second-line treatment and maintenance therapy.
•Availability of follow-up data.

排除标准

•Non-epithelial tumors, borderline tumors, clear cell carcinoma, mucinous carcinoma.
•Missing first-line or follow-up data.
•Non-epithelial tumors, borderline tumors, clear cell carcinoma, mucinous carcinoma.
•Patients with second relapse.
•Platinum-resistant patients, such as those who had disease progression during chemotherapy or within 6 months after platinum-based chemotherapy.
•Missing second-line or follow-up data.

结局指标

主要结局

Overall Mortality

时间窗: 11 years

Mortality of any cause

次要结局

未报告次要终点

研究者

发起方

Shanghai Gynecologic Oncology Group

申办方类型

Other Gov

责任方

Sponsor

相似试验

招募中

不适用

Prospective Cohort Study for Validation of Predictive Immune Biomarkers of Response to PAPR InhibitorsOvarian Cancer

NCT05640024Yonsei University54

招募中

不适用

Circulating Tumor DNA and BRCA Reversion Mutation in Advanced or Recurrent Ovarian Cancer Patients With Germline Mutation.Ovarian Cancer

NCT05458973Yonsei University100

尚未招募

2 期

Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance PatientsOvarian Cancer

NCT06544460Fudan University94

招募中

2 期

Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPiOvarian Cancer

NCT05551208Chongqing University Cancer Hospital42

Unknown

2 期

Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian CancerOvarian and Fallopian Tube Cysts and NeoplasmsOvarian CancerNeoplasms by SiteNeoplasmsGenital Neoplasms, FemaleUrogenital NeoplasmsNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeCarcinoma, Ovarian EpithelialOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleCarcinomaAnlotinibPARP InhibitorsBRCA1 MutationAngiogenesisAntineoplastic AgentsBRCA2 Mutation

NCT04566952Xiaoxiang Chen68